Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Menu

Megestrol Ace 40Mg/10Ml Susp 240 Ml By Roxane Labs

Image 0 of Megestrol Ace 40Mg/10Ml Susp 240 Ml By Roxane LabsImage 1 of Megestrol Ace 40Mg/10Ml Susp 240 Ml By Roxane Labs

Megestrol Ace 40Mg/10Ml Susp 240 Ml By Roxane Labs

Call for Price

Megestrol Ace 40Mg/10Ml Susp 240 Ml By Roxane Labs This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD3349131/RXB10030509/RXA316159
Size : 240 ML
Selling UoM : EA
NDC: 00054-3542-58
UPC Barcode : 300543542587
Supplier: 0050000335 ROXANE LABS MULTISOURCE (PGN)
Supplier Material : 354258
Generic Code : 021004 MEGESTROL ACETATE ORAL ORAL SUSP 400MG/1
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product

Have a question?

  Call for Price

Product Description.:

Suspension , white , lemon-lime

MEGACE? (megestrol acetate, USP) Oral Suspension contains megestrol acetate, a synthetic derivative of the naturally occurring steroid hormone, progesterone. Megestrol acetate is a white, crystalline solid chemically designated as 17α-(acetyloxy)-6-methylpregna-4,6-diene-3,20-dione. Solubility at 37? C in water is 2 ?g per mL, solubility in plasma is 24 ?g per mL.

MEGACE Oral Suspension is supplied as an oral suspension containing 40 mg of micronized megestrol acetate per mL.

MEGACE Oral Suspension contains the following inactive ingredients: alcohol (max. 0.06% v/v from flavor), citric acid, lemon-lime flavor, polyethylene glycol, polysorbate 80, purified water, sodium benzoate, sodium citrate, sucrose and xanthan gum.

INDICATIONS

MEGACE Oral Suspension is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS).
DOSAGE AND ADMINISTRATION

The recommended adult initial dosage of MEGACE Oral Suspension is 800 mg/day (20 mL/day). Shake container well before using.

In clinical trials evaluating different dose schedules, daily doses of 400 and 800 mg/day were found to be clinically effective.

A plastic dosage cup with 10 mL and 20 mL markings is provided for convenience.

SIDE EFFECTS
Clinical Adverse Events

Adverse events which occurred in at least 5% of patients in any arm of the two clinical efficacy trials and the open trial are listed below by treatment group. All patients listed had at least one post baseline visit during the 12 study weeks. These adverse events should be considered by the physician when prescribing MEGACE (megestrol acetate, USP) Oral Suspension.

DRUG INTERACTIONS

Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs. The effects of zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.